Evotec's April Report: A Pivotal Moment for the Troubled Biotech

Evotec's annual report on April 8th is crucial. After major losses, investors seek proof its restructuring and Sandoz deal can restore profitability.

The upcoming annual report from German drug discovery firm Evotec SE represents a critical juncture for the company and its investors. Following a difficult 2025 marked by significant losses and a crisis of confidence, the April 8th release of final figures and the new year's outlook will be scrutinized for evidence of a successful operational turnaround.

A Strategic Overhaul to Restore Profitability

In response to recent challenges, Evotec has embarked on a radical restructuring plan aimed squarely at improving margins. The company's aggressive cost-cutting initiative exceeded initial expectations, reducing expenditures by over €60 million in 2025—double the original target.

A cornerstone of this new direction is the transaction with generics manufacturer Sandoz. Valued at more than $650 million in total, including approximately $350 million in cash, the deal is designed to streamline Evotec's business model. The strategic shift moves the company away from capital-intensive assets and toward higher-margin technology licenses and milestone payments.

Mixed Operational Signals and Share Price Pressure

Despite strategic progress, operational performance remains strained. Financial results for the first nine months of 2025 painted a contradictory picture: while the Biologics division (JEB) posted growth exceeding 11%, the crucial Discovery & Predevelopment segment contracted by more than 12%. This resulted in an adjusted EBITDA loss nearing €17 million.

This operational weakness is reflected in the equity's performance. Over a twelve-month period, the stock has shed nearly 30% of its value, currently trading at €5.86. A modest stabilization has occurred since the start of the year, with shares gaining roughly 5.6%, but they remain well below the 52-week high of over €8.

Cautious Market Sentiment and Divergent Analyst Views

Market trust, shaken by the departure of former CEO Werner Lanthaler, a cyberattack, and multiple guidance reductions, has not fully recovered. Analyst opinions reflect this ongoing caution, though views are split. Researchers at Berenberg and RBC express optimism with a price target of €10, whereas Deutsche Bank maintains a more conservative stance with a €6 target, suggesting limited near-term upside.

All Eyes on April 8th

The date for a potential re-rating is set. Evotec's presentation on April 8th, containing the final 2025 accounts and the crucial forecast for the current year, will be decisive. Should management outline a credible path back to profitable growth, it could lay the foundation for a sustained recovery. Another disappointing outlook, however, risks unraveling the recent stabilization effort.